Callos Andrew 4

What Happened

• Andrew Callos, EVP & Chief Commercial Officer of Cytokinetics (CYTK), exercised options and sold shares on Feb 5, 2026. The filing shows he acquired 15,000 shares by exercising options at $23.26 (cost $348,900) and sold 15,000 shares in the open market at $61.93 for gross proceeds of $928,950. The filing also reports a disposition of 15,000 shares at $0.00 related to the option conversion.

Key Details

• Transaction date: 2026-02-05.
• Exercise: 15,000 shares acquired at $23.26 (total $348,900).
• Open-market sale: 15,000 shares sold at $61.93 (gross proceeds $928,950).
• Derivative disposition: 15,000 shares recorded as disposed at $0.00 (reported as an M-code conversion/disposition).
• Shares owned after transaction: not specified in the provided filing data.
• Footnote: F1 — options vest over four years (1/4 after one year, then monthly over the next 36 months), subject to continued employment.
• Filing timeliness: report date and filing date are the same (2026-02-05), so the filing appears timely.

Context

• The M transaction code means options/derivatives were exercised/converted. Because the filing shows both an exercise and an immediate open-market sale, this is effectively a cashless outcome: options were exercised, some shares sold for proceeds, and a block of shares was recorded at $0.00 (commonly reported when shares are surrendered or withheld to cover exercise costs or tax withholding). Such transactions are frequently routine for executives exercising vested options and do not by themselves indicate a change in company outlook.